Generated by AI
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.
Website150 N. Radnor Chester Road
Radnor, PA, 19087
United States
The latest articles about MLYS.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about MLYS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.